Do analysts prefer MTEX or LTRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MTEX or LTRN more profitable?

Lantern Pharma has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Lantern Pharma's return on equity of -198.34% beat Mannatech's return on equity. Company Net Margins Return on Equity Return on Assets Mannatech -11.97% -2,383.34% -40.24% Lantern Pharma N/A -198.34% -129.08%

Do analysts prefer MTEX or GRDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend ZYBT or MTEX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ZYBT or MTEX?

Zhengye Biotechnology has higher earnings, but lower revenue than Mannatech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 2.36 -$9.98M N/A N/A Mannatech $108.04M 0.10 -$15.21M -$6.71 N/A

Does the media prefer ZYBT or MTEX?

In the previous week, Zhengye Biotechnology and Zhengye Biotechnology both had 2 articles in the media. Zhengye Biotechnology's average media sentiment score of 0.94 beat Mannatech's score of 0.93 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mannatech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MTEX or ELUT?

Elutia has a consensus price target of $6.00, suggesting a potential upside of 525.00%. Given Elutia's stronger consensus rating and higher probable upside, analysts plainly believe Elutia is more favorable than Mannatech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Elutia 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, MTEX or ELUT?

Elutia has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mannatech $108.04M 0.10 -$15.21M -$6.71 N/A Elutia $12.29M 3.34 $53.38M $0.86 1.12

Is MTEX or ELUT more profitable?

Elutia has a net margin of 312.09% compared to Mannatech's net margin of -11.97%. Elutia's return on equity of 0.00% beat Mannatech's return on equity. Company Net Margins Return on Equity Return on Assets Mannatech -11.97% -2,383.34% -40.24% Elutia 312.09% N/A -53.97%

Does the media favor MTEX or ELUT?

In the previous week, Elutia had 2 more articles in the media than Mannatech. MarketBeat recorded 4 mentions for Elutia and 2 mentions for Mannatech. Mannatech's average media sentiment score of 0.93 beat Elutia's score of 0.72 indicating that Mannatech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mannatech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MIRA or MTEX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Mannatech (MTEX) Competitors

$5.50 0.00 (0.00%)

As of 06/12/2026 04:00 PM Eastern

Compare

MTEX vs. LTRN, GRDX, ZYBT, ELUT, and MIRA

Should you buy Mannatech stock or one of its competitors? MarketBeat compares Mannatech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mannatech include Lantern Pharma (LTRN), Entero Therapeutics (GRDX), Zhengye Biotechnology (ZYBT), Elutia (ELUT), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.

How does Mannatech compare to Lantern Pharma?

Mannatech (NASDAQ:MTEX) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Mannatech has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market.

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mannatech has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.10	-$15.21M	-$6.71	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lantern Pharma has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Lantern Pharma's return on equity of -198.34% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Lantern Pharma	N/A	-198.34%	-129.08%

In the previous week, Mannatech had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 2 mentions for Mannatech and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.87 beat Mannatech's score of 0.93 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Mannatech	Positive
Lantern Pharma	Very Positive

Summary

Mannatech and Lantern Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Mannatech compare to Entero Therapeutics?

Mannatech (NASDAQ:MTEX) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Mannatech has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Entero Therapeutics has lower revenue, but higher earnings than Mannatech. Entero Therapeutics is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.10	-$15.21M	-$6.71	N/A
Entero Therapeutics	$74.46K	470.88	-$6.39M	-$1.88	N/A

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 41.5% of Mannatech shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Mannatech had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Mannatech and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat Mannatech's score of 0.93 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Mannatech	Positive
Entero Therapeutics	Very Positive

Entero Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Entero Therapeutics' return on equity of -49.81% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Entero Therapeutics	N/A	-49.81%	-11.02%

Summary

Entero Therapeutics beats Mannatech on 8 of the 14 factors compared between the two stocks.

How does Mannatech compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Zhengye Biotechnology and Zhengye Biotechnology both had 2 articles in the media. Zhengye Biotechnology's average media sentiment score of 0.94 beat Mannatech's score of 0.93 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mannatech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zhengye Biotechnology has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Zhengye Biotechnology's return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Mannatech	-11.97%	-2,383.34%	-40.24%

13.0% of Mannatech shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zhengye Biotechnology has a beta of -2.4, indicating that its share price is 340% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

Zhengye Biotechnology has higher earnings, but lower revenue than Mannatech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	2.36	-$9.98M	N/A	N/A
Mannatech	$108.04M	0.10	-$15.21M	-$6.71	N/A

Summary

Zhengye Biotechnology beats Mannatech on 6 of the 10 factors compared between the two stocks.

How does Mannatech compare to Elutia?

Mannatech (NASDAQ:MTEX) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

In the previous week, Elutia had 2 more articles in the media than Mannatech. MarketBeat recorded 4 mentions for Elutia and 2 mentions for Mannatech. Mannatech's average media sentiment score of 0.93 beat Elutia's score of 0.72 indicating that Mannatech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mannatech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elutia has a net margin of 312.09% compared to Mannatech's net margin of -11.97%. Elutia's return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Elutia	312.09%	N/A	-53.97%

Elutia has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.10	-$15.21M	-$6.71	N/A
Elutia	$12.29M	3.34	$53.38M	$0.86	1.12

Elutia has a consensus price target of $6.00, suggesting a potential upside of 525.00%. Given Elutia's stronger consensus rating and higher probable upside, analysts plainly believe Elutia is more favorable than Mannatech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 27.6% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Mannatech has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Elutia has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Summary

Elutia beats Mannatech on 12 of the 16 factors compared between the two stocks.

How does Mannatech compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

MIRA Pharmaceuticals has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Mannatech has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

MIRA Pharmaceuticals has higher earnings, but lower revenue than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Mannatech	$108.04M	0.10	-$15.21M	-$6.71	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mannatech had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Mannatech and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.94 beat Mannatech's score of 0.93 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Positive
Mannatech	Positive

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MIRA Pharmaceuticals has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. MIRA Pharmaceuticals' return on equity of -140.82% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Mannatech	-11.97%	-2,383.34%	-40.24%

Summary

MIRA Pharmaceuticals beats Mannatech on 10 of the 14 factors compared between the two stocks.

Get Mannatech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MTEX vs. The Competition

Export

Metric	Mannatech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.62M	$2.99B	$6.52B	$12.05B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-0.82	18.84	24.00	24.42
Price / Sales	0.10	455.32	533.77	123.88
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	-2.00	3.98	10.55	6.82
Net Income	-$15.21M	$75.79M	$3.57B	$337.56M
7 Day Performance	-2.31%	1.57%	0.59%	1.16%
1 Month Performance	30.33%	-0.73%	1.55%	3.16%
1 Year Performance	-41.53%	23.44%	25.41%	30.60%

Mannatech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MTEX Mannatech	1.7567 of 5 stars	$5.50 flat	N/A	-41.5%	$10.62M	$108.04M	N/A	250	Gap Up
LTRN Lantern Pharma	1.4054 of 5 stars	$3.81 +1.6%	N/A	+27.2%	$43.09M	N/A	N/A	20	Positive News Gap Up
GRDX Entero Therapeutics	1.0595 of 5 stars	$6.37 +2.4%	N/A	N/A	$42.38M	$74.46K	N/A	9	Positive News Gap Down
ZYBT Zhengye Biotechnology	0.9184 of 5 stars	$0.89 +3.1%	N/A	-86.9%	$42.23M	$116.36M	N/A	278
ELUT Elutia	4.0745 of 5 stars	$0.97 -2.0%	$6.00 +518.6%	-46.1%	$41.50M	$12.29M	1.13	180	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MTEX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mannatech (MTEX) Competitors

MTEX vs. LTRN, GRDX, ZYBT, ELUT, and MIRA

How does Mannatech compare to Lantern Pharma?

Summary

How does Mannatech compare to Entero Therapeutics?

Summary

How does Mannatech compare to Zhengye Biotechnology?

Summary

How does Mannatech compare to Elutia?

Summary

How does Mannatech compare to MIRA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTEX vs. The Competition

Mannatech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mannatech (MTEX) Competitors

MTEX vs. LTRN, GRDX, ZYBT, ELUT, and MIRA

How does Mannatech compare to Lantern Pharma?

Which has more volatility & risk, MTEX or LTRN?

Do institutionals & insiders have more ownership in MTEX or LTRN?

Which has higher valuation & earnings, MTEX or LTRN?

Do analysts prefer MTEX or LTRN?

Is MTEX or LTRN more profitable?

Does the media refer more to MTEX or LTRN?

Summary

How does Mannatech compare to Entero Therapeutics?

Which has more risk and volatility, MTEX or GRDX?

Do analysts prefer MTEX or GRDX?

Which has preferable earnings and valuation, MTEX or GRDX?

Do insiders & institutionals hold more shares of MTEX or GRDX?

Does the media refer more to MTEX or GRDX?

Is MTEX or GRDX more profitable?

Summary

How does Mannatech compare to Zhengye Biotechnology?

Do analysts recommend ZYBT or MTEX?

Does the media prefer ZYBT or MTEX?

Is ZYBT or MTEX more profitable?

Do institutionals and insiders believe in ZYBT or MTEX?

Which has more volatility & risk, ZYBT or MTEX?

Which has stronger valuation and earnings, ZYBT or MTEX?

Summary

How does Mannatech compare to Elutia?

Does the media favor MTEX or ELUT?

Is MTEX or ELUT more profitable?

Which has preferable earnings & valuation, MTEX or ELUT?

Do analysts rate MTEX or ELUT?

Do insiders & institutionals have more ownership in MTEX or ELUT?

Which has more volatility & risk, MTEX or ELUT?

Summary

How does Mannatech compare to MIRA Pharmaceuticals?

Which has more risk & volatility, MIRA or MTEX?

Which has preferable valuation and earnings, MIRA or MTEX?

Do analysts rate MIRA or MTEX?

Does the media prefer MIRA or MTEX?

Do insiders and institutionals hold more shares of MIRA or MTEX?

Is MIRA or MTEX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTEX vs. The Competition

Mannatech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools